1. PharmaPATCH™
PharmaPATCH™ is a proprietary microneedle-enhanced delivery system designed to provide an efficient, minimally invasive, and potentially painless method for delivering drug candidates, including psychedelics. PharmaPATCH™ is intended to support at-home self-administration and incorporates anti-tampering and anti-abuse features. The Company has completed research studies demonstrating PharmaPATCH™ feasibility for delivering psychedelic compounds, including ketamine, DMT, psilocybin, MDMA, and LSD.
2. Ketamine
We have developed novel, exclusive ketamine assets for partnerships.
KetaRx™ (leveraging the Ketamine ANDA)
We entered into a definitive Asset Purchase Agreement to sell our Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP. The Agreement enables PharmaTher to participate in the potential long-term commercial success of the ANDA while maintaining meaningful exposure to the global ketamine market. It also allows the Company to focus on advancing next-generation ketamine programs, including long-acting injectables and novel delivery methods for potential psychiatric, pain, neurological, and orphan drug indications.
We entered into a definitive Asset Purchase Agreement to sell our Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP. The Agreement enables PharmaTher to participate in the potential long-term commercial success of the ANDA while maintaining meaningful exposure to the global ketamine market. It also allows the Company to focus on advancing next-generation ketamine programs, including long-acting injectables and novel delivery methods for potential psychiatric, pain, neurological, and orphan drug indications.
KetaVault™: A Gateway to Expedited Ketamine Development
Key Proprietary Information Includes:
Ketamine Clinical and Commercial Supply
PharmaTher offers to support partners' clinical and commercialization initiatives with a reliable supply of ketamine.
Key Proprietary Information Includes:
- Regulatory Filings: Investigational New Drug Applications.
- Comprehensive Drug Information: Investigator’s Brochures.
- Manufacturing Insights: Chemistry, Manufacturing, and Control data.
- Clinical Research & Data: Study protocols and research data for indications.
- Orphan Drug Designations: Access to information for Amyotrophic Lateral Sclerosis, Rett Syndrome, Complex Regional Pain Syndrome, Status Epilepticus, and ischemia/reperfusion injury.
- Novel Delivery Systems: Development programs and regulatory filings for PharmaTher's ketamine microneedle patch and subcutaneous wearable pump.
Ketamine Clinical and Commercial Supply
PharmaTher offers to support partners' clinical and commercialization initiatives with a reliable supply of ketamine.
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario, M5C 1P1
Canada
Tel: 1-888-846-3171
82 Richmond Street East
Toronto, Ontario, M5C 1P1
Canada
Tel: 1-888-846-3171
© COPYRIGHT 2026. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."